Marsh & McLennan Companies, Inc. vs Synopsys, Inc. — how do they compare? Marsh & McLennan Companies, Inc. trades at $175.94 (market cap $84.31B), while Synopsys, Inc. trades at $509.81 (market cap $95.39B). The key difference: Marsh & McLennan Companies, Inc. and Synopsys, Inc. are close in size by market cap, and Marsh & McLennan Companies, Inc. pays a 2.24% dividend while Synopsys, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Marsh & McLennan Companies, Inc. for 109 Days and Synopsys, Inc. for 71 Days on average.
| MRSH | SNPS | |
|---|---|---|
Market Cap | $84.31B | $95.39B |
Volume | 3,948,947 | 3,374,903 |
Sector | Financials | Technology |
52-Week High | $207.02 | $534.56 |
52-Week Low | $157.32 | $367.70 |
Typical Hold Time | 109 Days | 71 Days |
Enterprise Value | $104.99B | $102.62B |
Dividend Yield | 2.24% | — |
Signals from Pluang's Aura AI — not financial advice
MRSH trades at $176.16, up 1.44% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company completed the acquisition of Accel Holdings on October 2, 2026, expanding its advisory footprint. Revenue grew to $27.0B in 2025, with a net income margin of 15.41%, while valuation ratios like P/E of 21.57 and ROE of 25.72% reflect strong profitability. Analysts maintain a consensus price target of $202.71, though sentiment is mixed with a 'Hold' rating from most.
The outlook for MRSH is positive due to earnings momentum and strategic acquisitions, but risks include competitive pressures and potential margin compression. Upside remains if the company meets Q3 2026 EPS expectations of $1.97, supported by solid cash flow trends. Investors should weigh the high P/B ratio of 5.55 against growth prospects in the reinsurance sector.
Synopsys (SNPS) stock trades at $505.76, up 0.61% today, near its 52-week high. The technical picture is bullish with strong moving average support, though RSI levels suggest overbought conditions. Fundamentally, the company reported strong quarterly earnings beats and robust revenue growth, driven by AI partnerships with OpenAI and Amazon. Analyst sentiment is overwhelmingly positive with a 93% buy rating and a consensus price target of $572.54, indicating significant upside potential.
The outlook for SNPS is highly favorable, supported by AI-driven demand for chip design software and strategic acquisitions like Ansys. Key risks include high valuation multiples and integration challenges from recent deals. Investors should focus on execution of growth initiatives and monitor competitive pressures in the semiconductor design software market.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →